No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ABBV AbbVie
- 168.400
- -2.060-1.21%
Trading Jun 11 10:58 ET
297.37BMarket Cap50.12P/E (TTM)
170.640High168.400Low636.89KVolume170.100Open170.460Pre Close107.93MTurnover0.04%Turnover Ratio61.91P/E (Static)1.77BShares181.19652wk High37.14P/B296.72BFloat Cap125.84752wk Low5.99Dividend TTM1.76BShs Float181.196Historical High3.56%Div YieldTTM1.31%Amplitude20.362Historical Low169.462Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation Into Fairness of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Buyout and Encourages Investors to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) ("Cerevel") on behalf of the company's shareholders.On December 6,
Alvotech and Stada Add to Strategic Alliance Through Denosumab Partnership
AbbVie (ABBV) Laps the Stock Market: Here's Why
Express News | NYSE Order Imbalance 256442.0 Shares on Sell Side
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,100 Today
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.41% on an annualized basis producing an average annual return of 12.01%. Currently, AbbVie has a market capitalization of $29
AbbVie's Blood Cancer Treatment Receives Scottish Approval
AbbVie (4AB.F, ABBV.VI) received approval from the Scottish Medicines Consortium for its Tepkinly treatment for adults with an aggressive form of blood cancer. The treatment is for diffuse large B-cel
Comments
From YouTube
6
Interesting both for the (1) shift in the macro-trend to M&A (vs. Licensing) and (2) change in top spenders
$Merck & Co(MRK.US$ $Bristol-Myers Squibb(BMY.US$ $Johnson & Johnson(JNJ.US$ $Pfizer(PFE.US$ $Novo-Nordisk A/S(NVO.US$ $AbbVie(ABBV.US$
$Merck & Co(MRK.US$ $Bristol-Myers Squibb(BMY.US$ $Johnson & Johnson(JNJ.US$ $Pfizer(PFE.US$ $Novo-Nordisk A/S(NVO.US$ $AbbVie(ABBV.US$
10
1
Top 10 drug companies raked in NEARLY TRIPLE the revenue in 2023 ($491B) vs 2013 ($165B) 2013 vs. 2023.
$AbbVie(ABBV.US$ +189%
$Bristol-Myers Squibb(BMY.US$ +175%
$Johnson & Johnson(JNJ.US$ +95%
$AstraZeneca(AZN.US$ +78%
$NVM +45%
$Merck & Co(MRK.US$ +37%
$ROCHE HOLDING AG(RHHBY.US$ +27%
$Pfizer(PFE.US$ +13%
$GlaxoSmithKline(GSK.US$ +13%
----- $SPDR S&P 500 ETF(SPY.US$ +12% -----
$Sanofi(SNY.US$ +3%
Source: Arjun Murthy on the HR app!
$AbbVie(ABBV.US$ +189%
$Bristol-Myers Squibb(BMY.US$ +175%
$Johnson & Johnson(JNJ.US$ +95%
$AstraZeneca(AZN.US$ +78%
$NVM +45%
$Merck & Co(MRK.US$ +37%
$ROCHE HOLDING AG(RHHBY.US$ +27%
$Pfizer(PFE.US$ +13%
$GlaxoSmithKline(GSK.US$ +13%
----- $SPDR S&P 500 ETF(SPY.US$ +12% -----
$Sanofi(SNY.US$ +3%
Source: Arjun Murthy on the HR app!
6
1
Hello Mooers! ![]()
Recently, there have been signs that World War 3![]()
is coming (*1, *2, *3). Given the current status in the Middle East, Eastern Europe, and the Asia-Pacific, investing has become a difficult task. ![]()
In light of this hypothetical situation![]()
, I have chosen to invest from April 2024 to July 2024 using a three-pronged strategy. ![]()
![]()
![]()
Approach One: Buy the winners
Who are the winners?![]()
During wars, companies that are in the defense, oil, ...
Recently, there have been signs that World War 3
In light of this hypothetical situation
Who are the winners?
29
36
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg